ArticleBMJ case reports2014
Cerebellar ataxia and epilepsy with anti-GAD antibodies: treatment with IVIG and plasmapheresis.
Article in BMJ case reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Glutamic Acid Decarboxylase 65 Antibody-associated Epilepsy and Diplopia: Two Case Reports with Literature Review.Cerebellum (London, England) · 2024Review
- Ataxias: Hereditary, Acquired, and Reversible Etiologies.Seminars in neurology · 2023Article
- Therapeutic plasma exchange in the management of stiff person syndrome spectrum disorders: a case series and review of the literature.Therapeutic advances in neurological disorders · 2023Article
- Diagnosis and Clinical Features in Autoimmune-Mediated Movement Disorders.Journal of movement disorders · 2022Article
- Efficacy and safety of therapeutic plasma exchange in stiff person syndrome.Open medicine (Warsaw, Poland) · 2021Review
- Intravenous methylprednisolone or immunoglobulin for anti-glutamic acid decarboxylase 65 antibody autoimmune encephalitis: which is better?BMC neuroscience · 2020Article
- Anti-glutamic acid decarboxylase antibody (GAD) syndromes may have more aggressive disease course in African Americans and early onset of presentation compare to Caucasians group.eNeurologicalSci · 2019Article
- Article
- Immune-mediated Cerebellar Ataxias: Practical Guidelines and Therapeutic Challenges.Current neuropharmacology · 2019Review
- Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review.Journal of neural transmission (Vienna, Austria : 1996) · 2017Review
- Epigenetic Suppression of GADs Expression is Involved in Temporal Lobe Epilepsy and Pilocarpine-Induced Mice Epilepsy.Neurochemical research · 2016Article
- Anti-glutamic acid decarboxylase antibody positive neurological syndromes.Neurosciences (Riyadh, Saudi Arabia) · 2016Review
- Clinical Spectrum of Stiff Person Syndrome: A Review of Recent Reports.Tremor and other hyperkinetic movements (New York, N.Y.) · 2016Review
- Cerebellar Dysfunction and Ataxia in Patients with Epilepsy: Coincidence, Consequence, or Cause?Tremor and other hyperkinetic movements (New York, N.Y.) · 2016Article
- An anti-GAD autoantibody-associated cerebellar syndrome case: a curable cause of ataxia.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2015Article
- ILAE type 3 hippocampal sclerosis in patients with anti-GAD-related epilepsy.Neurology(R) neuroimmunology & neuroinflammation · 2015Article
- Guidelines for treatment of immune-mediated cerebellar ataxias.Cerebellum & ataxias · 2015Review
- Therapeutic role of plasma exchange in the management of stiff person syndrome: experience from a tertiary care centre.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glutamic acid decarboxylase autoantibody (GAD-65) catalyses glutamate conversion into γ-aminobutyric acid (GABA) in the central nervous system and in the pancreatic β cells. Antibodies targeting GAD-65 are of uncertain pathogenic significance and occur in stiff person syndrome, cerebellar ataxia, epilepsy, limbic encephalitis and combinations thereof and diabetes mellitus. A 45-year-old man with a cerebellar gait ataxia, dysmetria, nystagmus and mild cerebellar dysarthria was diagnosed with insulin-dependent diabetes mellitus a year after the onset of neurological symptoms. He also developed complex and tonic-clonic seizures, resistant to anticonvulsant medication and deteriorated cognitively. Blood and cerebrospinal fluid serology, and imaging supported the diagnosis of GAD-65 cerebellar ataxia and epilepsy. He was treated with intravenous immunoglobulin and subsequently plasmapheresis. We report the outcome of 3 years of treatment, which resulted in the improvement of cerebellar signs (particularly gait), with some ultimate decline of efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.